Yunge Zhao, MD, PhD, Mark Turlington, BS, Damien J. LaPar, MD, David R

Slides:

Advertisements

Similar presentations

Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model Yunge Zhao, MD, PhD, Jacob.

Advertisements

Bilateral Internal Mammary Artery Use for Coronary Artery Bypass Grafting Remains Underutilized: A Propensity-Matched Multi-Institution Analysis Damien.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Neonatal Flail Tricuspid Valve: Diagnosis and Management

Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model Yunge Zhao, MD, PhD, Jacob.

Bertrand Poussier, MD, Alfredo C

Comparison of Video-Assisted Thoracoscopic Surgery and Robotic Approaches for Clinical Stage I and Stage II Non-Small Cell Lung Cancer Using The Society.

Rodrigo A. S. Sardenberg, MD, Clovis Pinto, MD, Cynthia A

Collision Tumor of Esophagus: Report of Three Cases

Joshua E. Rosen, BASc, Hari B

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Dhruva K. Mishra, PhD, Steven D. Compean, BS, Michael J

Fate of Newly Detected Lesions During Postoperative Surveillance for Non-Small Cell Lung Cancer Jae-Ik Lee, MD, PhD, Young-Jin Lee, RN, Kook-Yang Park,

Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M

Armin Kiankhooy, MD, Matthew D. Taylor, MD, Damien J

Rapamycin Blocks Fibrocyte Migration and Attenuates Bronchiolitis Obliterans in a Murine Model Jacob R. Gillen, MD, Yunge Zhao, MD, PhD, David A. Harris,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia Michael J. Osgood, MD, Kevin Sexton, MD, Igor Voskresensky, MD, Kyle.

Short-Course Rapamycin Treatment Preserves Airway Epithelium and Protects Against Bronchiolitis Obliterans Jacob R. Gillen, MD, Yunge Zhao, MD, PhD,

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Hospital Variation in Mortality From Cardiac Arrest After Cardiac Surgery: An Opportunity for Improvement? Damien J. LaPar, MD, MS, Ravi K. Ghanta, MD,

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non- Small Cell Lung Cancer Paul J. Speicher, MD, Zachary W. Fitch,

Castigliano M. Bhamidipati, DO, MS, George J

David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Expression of Bone Morphogenetic Proteins in Human Lung Carcinomas

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

The Efficacy of Restaging Endobronchial Ultrasound in Patients With Non-Small Cell Lung Cancer After Preoperative Therapy Basil S. Nasir, MBBCh, Ayesha.

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Abbas Emaminia, MD, Damien J

The Society of Thoracic Surgeons General Thoracic Surgery Database: Establishing Generalizability to National Lung Cancer Resection Outcomes Damien J.

Joseph D. Whitlark, MD, RVT, Joseph A. Kirollos, Spencer M

Who Do You Say You Are? The Annals of Thoracic Surgery

Damien J. LaPar, MD, MS, James M. Isbell, MD, MSCI, Daniel P

Retinoic acid enhances lung growth after pneumonectomy

Use of Amiodarone After Major Lung Resection

Surgical Dilemmas: Diagnosis and Treatment of Atrial Plasmacytoma

Modified Ross Procedure to Prevent Autograft Dilatation

Type A Aortic Dissection With Cold Agglutinin Disease

Abel Gómez-Caro, MD, Pedro Arguis, MD The Annals of Thoracic Surgery

Risk Factors for Atrial Fibrillation After Lung Cancer Surgery: Analysis of The Society of Thoracic Surgeons General Thoracic Surgery Database Mark Onaitis,

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Hybrid Management of a Giant Left Main Coronary Artery Aneurysm

Patient Preferences in Treatment Choices for Early-Stage Lung Cancer

Neurofibromatosis of the Esophagus

Jonathan D. Spicer, MD, PhD, Jitesh B. Shewale, BDS, PhD, David B

Editorial Board, January 2010

Completely Thrombosed Tricuspid Pouch Mimicking a Cardiac Tumor

Daniel P. Mulloy, MD, Ashish K. Sharma, MBBS, PhD, Lucas G

Postoperative Pleural Effusion in Bronchioloalveolar Cancer

Vacuum-Assisted Closure for the Treatment of Complex Chest Wounds

Deterioration of a Tricuspid Bioprosthesis Due to Adhesion of the Native Valve Herbert Gutermann, MD, Willem Flameng, MD, PhD, Paul Herijgers, MD, PhD

Sara A. Hennessy, MD, Tjasa Hranjec, MD, MS, Brian R

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Daniel A. Anaya, MD, Mujun Yu, MD, Riyad Karmy-Jones, MD

Invited Commentary The Annals of Thoracic Surgery

Robert Lee Replogle, September 30, 1931–May 9, 2016

Digital Drainage System Reduces Hospitalization After Video-Assisted Thoracoscopic Surgery Lung Resection Daniel L. Miller, MD, Gerald A. Helms, MD,

Treatment Outcomes of Patients With Different Subtypes of Large Cell Carcinoma of the Lung Yung-Han Sun, MS, Shih-Wei Lin, PhD, Chih-Cheng Hsieh, MD,

The American Board of Thoracic Surgery: Update

Gorav Ailawadi, MD, Damien J. LaPar, MD, Brian R

Mark I. Block, MD The Annals of Thoracic Surgery

Late Consequences of a Much Earlier Decision

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

The Impact of New Technology on Cardiothoracic Surgical Practice

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Leukocytosis and Increased Risk of Atrial Fibrillation After General Thoracic Surgery David Amar, MD, Anuj Goenka, BS, Hao Zhang, MD, Bernard Park, MD,

Benjamin D. Kozower, MD, MPH, Shubin Sheng, PhD, Sean M

J. Alberto Lopez, MD The Annals of Thoracic Surgery

Presentation transcript:

Characterization of Novel Synthesized Small Molecular Compounds Against Non-Small Cell Lung Cancer Yunge Zhao, MD, PhD, Mark Turlington, BS, Damien J. LaPar, MD, David R. Jones, MD, David A. Harris, BS, Irving L. Kron, MD, Lin Pu, PhD, Christine L. Lau, MD The Annals of Thoracic Surgery Volume 92, Issue 3, Pages 1031-1037 (September 2011) DOI: 10.1016/j.athoracsur.2011.04.081 Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Antitumor activities of our newly synthesized compounds. (A) The anti-lung carcinoma cell activities of PL54S (5 to 20 μΜ) in A549, H23, H1975, and H4226. Mean ± SEM values from 3 separate experiments for each group are shown. (B) Comparison of H23 cells treated with PL54S, PL54R, and PL54Rac. H23 cells were grown in 96 well plates with RPMI media fortified with 10% FBS for 24 hours and then treated with 5, 10, and 20 μM of PL54S, PL54R, and PL54Rac for another 24 hours. The cells were stained with 0.1% crystal violet. Images were taken under microscope with 60× magnification. DMSO was used as the control. (DMSO = dimethyl sulfoxide; FBS = fetal bovine serum; RPMI = Roswell Park Memorial Institute; SEM = standard error of the mean.) The Annals of Thoracic Surgery 2011 92, 1031-1037DOI: (10.1016/j.athoracsur.2011.04.081) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Determination of dead cells after treatment with PL54 enantiomers in A549 and H23 cells. The cells were stained with 0.4% wt/vol trypan blue for 5 minutes. The number of cells per high-power (HP) field were counted. Data shown are the mean ± SEM values from 3 separate experiments for each group. (DMSO = dimethyl sulfoxide; SEM = standard error of the mean.) The Annals of Thoracic Surgery 2011 92, 1031-1037DOI: (10.1016/j.athoracsur.2011.04.081) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Effects of PL54 enantiomers on colony formation in H23 cells. (A) Colony numbers per well after treatment with PL54 compounds for 10 days. (B) Colony number per well after treatment with PL54 compound for 24 hours and then grew for another 10 days without compounds. Data shown are the mean ± SEM values from 3 separate experiments for each group. (DMSO = dimethyl sulfoxide; SEM = standard error of the mean.) The Annals of Thoracic Surgery 2011 92, 1031-1037DOI: (10.1016/j.athoracsur.2011.04.081) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 Effects of PL54 enantiomers on cell proliferation and cell invasion of A549. (A) PL54 enantiomers (5 to 20 μM) inhibited A549 cell proliferation. DMSO was used as the control. Data shown are the mean ± SEM values from 3 separate experiments for each group. (B) PL54 enantiomers (10 μM) blocked A549 cell invasion. DMSO was used as the control. Data shown are the mean ± SEM values from 3 separate experiments for each group. (DMSO = dimethyl sulfoxide; SEM = standard error of the mean.) The Annals of Thoracic Surgery 2011 92, 1031-1037DOI: (10.1016/j.athoracsur.2011.04.081) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

Fig 5 Effects of PL54 enantiomers on soft agar colony formation of lung carcinoma cells. (A) Colony formation in A549 cells and H23 cells treated with PL54 compounds. PL54 enantiomers (10 μM) were added to the top agar. DMSO was used as the control. Images photographed under microscopes at 10× magnification. (B) Colony number in A549, H23, H1975, and H4226 cells after PL54 treatment with enantiomers. The number of colonies per well was counted. Data shown are the mean ± SEM values from thr3ee separate experiments for each group. (DMSO = dimethyl sulfoxide; SEM = standard error of the mean.) The Annals of Thoracic Surgery 2011 92, 1031-1037DOI: (10.1016/j.athoracsur.2011.04.081) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions